Table 4.
Analysis of secondary outcomes (new prescriptions for antidiabetic drugs, self monitoring of blood glucose, diagnosis of diabetes in Ontario Diabetes Database) in new users of statins
| Statin | No of patients | No of outcomes | Median (IQR) follow-up (person days) | No of outcomes per 1000 person years | HR (95% CI) | Number needed to treat to harm | |
|---|---|---|---|---|---|---|---|
| Unadjusted | Adjusted* | ||||||
| Pravastatin | 38 470 | 1713 | 236 (90-1080) | 27.07 | Reference | Reference | — |
| Atorvastatin | 268 254 | 18 303 | 360 (89-1256) | 37.28 | 1.39 (1.33 to 1.46) | 1.21 (1.15 to 1.27) | 140 |
| Fluvastatin | 5636 | 193 | 188 (66-732) | 24.99 | 0.90 (0.78 to 1.05) | 0.91 (0.79 to 1.06) | — |
| Lovastatin | 6287 | 260 | 207 (90-927) | 27.06 | 0.99 (0.87 to 1.13) | 1.03 (0.90 to 1.17) | — |
| Rosuvastatin | 76 774 | 4565 | 300 (50-796) | 42.35 | 1.53 (1.45 to 1.62) | 1.15 (1.08 to 1.22) | 202 |
| Simvastatin | 75 829 | 4477 | 323 (90-1355) | 31.84 | 1.19 (1.13 to 1.26) | 1.11 (1.05 to 1.18) | 261 |
*Adjusted for age, sex, year of cohort entry, recent acute coronary syndrome, chronic coronary artery disease, Charlson score, previous use of diuretic (thiazide), nitroglycerin, angiotensin receptor blocker, β blocker, hormones and analogues.